Carboxymethylcellulose

Identification

Name
Carboxymethylcellulose
Accession Number
DB11059
Type
Small Molecule
Groups
Approved, Investigational
Description

Carboxymethylcellulose is a cellulose derivative that consists of the cellulose backbone made up of glucopyranose monomers and their hydroxyl groups bound to carboxymethyl groups. It is added in food products as a viscosity modifier or thickener and emulsifier. It is also one of the most common viscous polymers used in artificial tears, and has shown to be effective in the treatment of aqueous tear-deficient dry eye symptoms and ocular surface staining [1]. The viscous and mucoadhesive properties as well as its anionic charge allow prolonged retention time in the ocular surface [1]. Sodium carboxymethylcellulose is the most commonly used salt.

Synonyms
  • Carbose
  • Carboxymethyl cellulose
  • Carmellose
  • Carmelosa
  • Cellulose carboxymethyl ether
  • Cellulose gum
  • Cellulose, carboxymethyl ether
  • Thylose
Product Ingredients
IngredientUNIICASInChI Key
Carboxymethylcellulose sodiumK679OBS3119004-32-4Not applicable
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acne Pimple Master PatchPatch30 mg/10gTopicalCosrx Inc.2015-12-282015-12-31Us
Artificial TearsSolution / drops10 mg/1mLOphthalmicAru Pharma Inc.2018-01-22Not applicableUs
Biolle Gel TearsSolution / drops10 mg/1mLOphthalmicSage Ethnographic Research, Dba Biollé2015-06-01Not applicableUs
Biolle TearsSolution / drops5 mg/1mLOphthalmicSage Ethnographic Research, Dba Biollé2015-06-01Not applicableUs
Carboxymethylcellulose sodiumSolution5 mg/1mLOphthalmicPromed Exports Private Limited2009-10-01Not applicableUs
CareOne LubricantSolution / drops5 mg/1mLOphthalmicFoodhold U.S.A.2017-05-18Not applicableUs
CareOne Lubricant Eye PlusSolution / drops0.5 g/100mLOphthalmicAmerican Sales Company2013-06-20Not applicableUs
Cellufresh Liq 0.5%Liquid0.5 %OphthalmicAllergan1992-12-312000-06-01Canada
Cho-A DermDressing130 g/433gTopicalCho-A Pharm.Co.,Ltd.2018-06-19Not applicableUs
CMC Lubricant Eye DropsSolution / drops5 mg/1mLOphthalmicAmerisource Bergen2013-03-22Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Clear Eyes for Dry EyesCarboxymethylcellulose sodium (1.0 %) + Glycerin (0.25 %)SolutionOphthalmicPrestige Brands Inc2008-03-262014-03-20Canada
CVS Moisturizing Lubricating EyeCarboxymethylcellulose sodium (5 mg/100mg) + Glycerin (9 mg/100mg)Solution / dropsOphthalmicCVS Health2013-09-03Not applicableUs
CVS Moisturizing Lubricating Eye Twin PackCarboxymethylcellulose sodium (5 mg/1mL) + Glycerin (9 mg/1mL)Solution / dropsOphthalmicCVS Health2014-07-10Not applicableUs
Equate ComfortCarboxymethylcellulose sodium (2.5 mg/1mL) + Hypromellose (3 mg/1mL)GelOphthalmicWalmart Stores2014-04-10Not applicableUs
Equate Day and Night Restore TearsCarboxymethylcellulose sodium (5 mg/1mL) + Mineral oil (425 mg/1g) + Petrolatum (573 mg/1g)KitWalmart Stores2018-06-01Not applicableUs
Equate Lubricating EyeCarboxymethylcellulose sodium (5 mg/1mL) + Glycerin (9 mg/1mL)Solution / dropsOphthalmicWalmart Stores2012-04-01Not applicableUs
Equate Restore Dual LubricatingCarboxymethylcellulose sodium (5 mg/1mL) + Glycerin (9 mg/1mL)Solution / dropsOphthalmicWalmart2018-03-01Not applicableUs
Equate Restore Dual Sensitive LubricantCarboxymethylcellulose sodium (5 mg/1mL) + Glycerin (9 mg/1mL)Solution / dropsOphthalmicWalmart Stores2016-05-03Not applicableUs
Genteal GeldropsCarboxymethylcellulose sodium (0.25 %) + Hypromellose (0.3 %)SolutionOphthalmicAlcon, Inc.2007-01-032014-01-13Canada
GenTeal Moderate to SevereCarboxymethylcellulose sodium (2.5 mg/1mL) + Hypromellose (3 mg/1mL)GelOphthalmicNovartis2009-09-14Not applicableUs
Categories
UNII
05JZI7B19X
CAS number
9000-11-7
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Indicated for the symptomatic relief of burning, irritation and discomfort of the eyes due to dryness or exposure to wind or sun.

Pharmacodynamics

In a randomized clinical study of patients with mild or moderate forms of eye dryness, ophthalmic treatment with sodium carboxymethylcellulose resulted in a diminished frequency of symptoms compared to the placebo group [2]. Carboxymethylcellulose interacts with human corneal epithelial cells to facilitate corneal epithelial wound healing and attenuate eye irritation in a dose-dependent manner [1]. It exhibits protective actions on the ocular surface in various applications; it mediates cytoprotective effects on the ocular surface when applied prior to contact lenses and reduces the incidence of epithelial defects during LASIK [1].

Mechanism of action

Carboxymethylcellulose binds to the surface of corneal epithelial cells via its glucopyranose subunits binding to glucose receptors GLUT-1 [1]. The residence time of carboxymethylcellulose bound to corneal cells is approximately 2 hours as indicated by a short-term binding assay [1]. Binding of carboxymethylcellulose to the matrix proteins stimulated corneal epithelial cell attachment, migration, and re-epithelialization of corneal wounds [1].

TargetActionsOrganism
USolute carrier family 2, facilitated glucose transporter member 1
binder
Human
Absorption

No pharmacokinetic data available.

Volume of distribution

No pharmacokinetic data available.

Protein binding

No pharmacokinetic data available.

Metabolism

No pharmacokinetic data available.

Route of elimination

No pharmacokinetic data available.

Half life

No pharmacokinetic data available.

Clearance

No pharmacokinetic data available.

Toxicity

Rat oral LD50, rabbit dermal LD50, and rat inhalation LC50 of sodium carboxymethyl cellulose are 27000 mg/kg, >2 g/kg, and >5800 mg/m^3 (4 hours), respectively [MSDS].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Carboxymethylcellulose.
AclidiniumThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Aclidinium.
AgmatineThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Agmatine.
AlcuroniumThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Alcuronium.
AlfentanilThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Alfentanil.
AlphacetylmethadolThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Alphacetylmethadol.
AlphaprodineThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Alphaprodine.
AmantadineThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Amantadine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Carboxymethylcellulose.
AmiodaroneThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Amiodarone.
Food Interactions
Not Available

References

General References
  1. Garrett Q, Simmons PA, Xu S, Vehige J, Zhao Z, Ehrmann K, Willcox M: Carboxymethylcellulose binds to human corneal epithelial cells and is a modulator of corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1559-67. doi: 10.1167/iovs.06-0848. [PubMed:17389485]
  2. Bruix A, Adan A, Casaroli-Marano RP: [Efficacy of sodium carboxymethylcellulose in the treatment of dry eye syndrome]. Arch Soc Esp Oftalmol. 2006 Feb;81(2):85-92. [PubMed:16511715]
External Links
PubChem Substance
347911098
ChEMBL
CHEMBL1909054
Wikipedia
Carboxymethylcellulose
AHFS Codes
  • 28:20.00 — Anorexigenic Agents & Respiratory and CNS Stimulants
  • 52:13.00* — Artificial Tears
  • 52:92.00 — EENT Drugs, Miscellaneous
MSDS
Download (34 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedOtherCancer, Breast / Inflammatory carcinoma of the breast / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
1CompletedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)1
1CompletedTreatmentAlkylating Agent-Related Acute Myeloid Leukemia / Chronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Refractory Anemia With Excess Blasts in Transformation1
1RecruitingTreatmentBlasts 30 Percent or Less of Bone Marrow Nucleated Cells / Chronic Myelomonocytic Leukemia / High Risk Myelodysplastic Syndrome / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Refractory Anemia1
1RecruitingTreatmentProstate Cancer1
1, 2Active Not RecruitingTreatmentCorneal Graft Failure / Corneal Neovascularization1
1, 2CompletedTreatmentCorneal Graft Failure / Corneal Neovascularization1
1, 2RecruitingTreatmentFallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Carcinoma1
1, 2SuspendedTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2CompletedTreatmentDry Eye Syndrome (DES)1
2Not Yet RecruitingTreatmentAnatomic Stage IV Breast Cancer AJCC v8 / Estrogen Receptor Negative / HER2/Neu Negative / Metastatic Triple-Negative Breast Carcinoma / Progesterone Receptor Negative / Prognostic Stage IV Breast Cancer AJCC v81
2RecruitingNot AvailableNeuroendocrine Tumors1
2RecruitingTreatmentEye Dryness1
2WithdrawnNot AvailableCystoid Macular Edema1
2WithdrawnTreatmentAdenoviral Conjunctivitis1
2, 3CompletedTreatmentEye Dryness1
3CompletedTreatmentBilateral LASIK Surgery1
3CompletedTreatmentContact Lens Lubrication1
3CompletedTreatmentDry Eye Syndrome (DES)1
3CompletedTreatmentDry Eye Syndromes3
3CompletedTreatmentEye Dryness1
4CompletedNot AvailableHistamine Responsive Allergy Patients1
4CompletedTreatmentCataracts / Dry Eye Syndromes1
4CompletedTreatmentDry Eye Syndromes3
4CompletedTreatmentHypotrichosis1
4Not Yet RecruitingPreventionMyopia1
4RecruitingTreatmentCervical Preparation / Pain NOS / Pregnancy Termination1
4RecruitingTreatmentDry Eye Syndromes1
4Unknown StatusPreventionBlindness / Retinal Detachment / Retinopathy of Prematurity1
4Unknown StatusTreatmentDry Eye Syndromes1
Not AvailableCompletedTreatmentDry Eye Syndrome (DES)2
Not AvailableCompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Pseudoexfoliation Syndrome1
Not AvailableTerminatedTreatmentOral Lichen Planus1
Not AvailableUnknown StatusTreatmentEye Dryness1
Not AvailableWithdrawnTreatmentCorneas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
PatchTopical30 mg/10g
Solution / dropsOphthalmic10 mg/1mL
SolutionOphthalmic5 mg/1mL
LiquidOphthalmic0.5 %
DressingTopical130 g/433g
Solution / dropsOphthalmic
Kit
LiquidIntraocular5 mg/1mL
SolutionOphthalmic
GelOphthalmic
Solution, gel forming / dropsOphthalmic0.5 g/100mL
Solution / dropsOphthalmic0.5 g/100mL
Solution, gel forming / dropsOphthalmic.5 g/100mL
Solution / dropsOphthalmic.5 g/100mL
PatchTopical1.05 g/3.5g
CapsuleOral300 mg
PasteOral; Topical
Solution / dropsOphthalmic0.25 %
Solution / dropsOphthalmic1 %
SolutionOphthalmic0.5 %
SolutionOphthalmic10 mg
EmulsionOphthalmic
Solution / dropsOphthalmic5 mg
Solution / dropsOphthalmic0.5 %
Solution / dropsOphthalmic5 mg/1mL
Kit; solutionOphthalmic
AerosolOral
GelOphthalmic10 mg/1mL
Solution / dropsOphthalmic2.5 mg/1mL
SolutionOphthalmic0.25 %
PatchTopical36.87 mg/241
PatchTopical6.17 mg/101
PatchTopical12.58 mg/51
PatchTopical18.12 mg/91
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)300MSDS
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Xenobiotic transporter activity
Specific Function
Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including b...
Gene Name
SLC2A1
Uniprot ID
P11166
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 1
Molecular Weight
54083.325 Da
References
  1. Garrett Q, Simmons PA, Xu S, Vehige J, Zhao Z, Ehrmann K, Willcox M: Carboxymethylcellulose binds to human corneal epithelial cells and is a modulator of corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1559-67. doi: 10.1167/iovs.06-0848. [PubMed:17389485]

Drug created on December 03, 2015 09:51 / Updated on November 14, 2018 12:58